rsz crawford010317 108 117 Revolutionary Northern wound dressing gets green light for U.S use

Revolutionary Northern wound dressing gets green light for U.S use

Feb 15, 2017 | Latest News |

Crawford Healthcare has received United States Food and Drug Administration (FDA) clearance for a world-first wound dressing developed in the Northern Powerhouse. The product, developed in partnership with The University of Manchester, is the first FDA-cleared absorbent gelling dressing containing unique Oxysalt technology. It will initially be available for clinical use in the U.S – the world’s largest market for advanced wound care, representing almost half of global spend.

“The North West is renowned for the quality of its Life Sciences sector, and the innovations created here are testament to the exceptional cluster of universities and businesses fostering research and development.  It fills me with immense pride to see world-leading research conducted between the University and a local partner making a real difference to healthcare and promoting the capabilities of the Northern Powerhouse.”


Professor Ian Greer, Vice-President and Dean of the University of Manchester’s Faculty of Biology, Medicine and Health

The unique and revolutionary elements of the silver-based dressing focus on its unrivalled ability to disrupt and kill anti-microbial biofilms – bacteria encased in a protective matrix that can up to 1,000 times resistance to antibiotics. The dressing helps chronic wounds, such as diabetic ulcers and pressure sores, to heal. Crawford, which is the UK’s fourth largest advanced wound care business, secured the exclusive proprietary rights to the dressing’s class-leading Oxysalt technology in early 2016 and is currently developing its inclusion in a range of treatments for international use.

“The U.S wound care market is expected to be worth in excess of $12billion by 2018, making it the most important territory in terms of growing our global market share. Our growth strategy has always been to replicate the success of our highly profitable UK model overseas and this unrivalled product gives us the opportunity to do it in the world’s biggest market, where demographic trends point towards an aging population and increasing levels of healthcare spend related to diabetes.”


Richard Anderson, CEO, Crawford Healthcare